Philip Morris International Inc is not a strong buy at the moment for a beginner investor with a long-term perspective. While the company has shown strong growth in its smoke-free product segment and exceeded Q1 earnings expectations, the technical indicators are mixed, and insider selling has surged significantly. Additionally, the stock is currently trading in a bearish moving average pattern, and analysts have recently lowered price targets. Given the investor's background and preference for long-term investments, it would be prudent to hold off on buying until a clearer entry point emerges.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 71.816, and the moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 168.042), and the pre-market price is down 1.60%. Key support levels are at 154.52, with resistance at 172.22.

Q1 2026 earnings exceeded expectations with a 9.1% revenue increase and 11.9% growth in smoke-free product shipments.
The Trump administration's reclassification of cannabis may indirectly benefit Philip Morris if it explores opportunities in the cannabis market.
Insider selling has surged by 5021.37% over the last month, signaling potential lack of confidence from insiders.
Analysts have recently lowered price targets, citing concerns over forex impacts and lower Zyn shipments.
In Q1 2026, revenue increased by 9.09% YoY to $10.15 billion, driven by strong smoke-free product growth. However, net income dropped to $0 (-100% YoY), and EPS declined by 9.30% YoY to $1.56. Gross margin improved slightly to 68.06%.
Recent analyst ratings are mixed. UBS and Morgan Stanley lowered price targets to $168 and $190, respectively, while maintaining Neutral and Overweight ratings. Stifel and Argus maintain Buy ratings with price targets of $195 and $210, citing strong smoke-free product growth and earnings acceleration potential.